Cardium Therapeutics just reported that its professional-use Excellagen® (formulated collagen gel 2.6%) wound care product has been named one of the top ten podiatry innovations this year by the publication Podiatry Today. The company also told investors that it will be introducing the wound care product at the American Podiatric Medical Association (APMA) National Meeting (Booth 1910) being held August 16 – 19, 2012, in Washington, DC.
The report, titled “The Top 10 Innovations in Podiatry,” noted that “the product’s full-length collagen molecules are in their natural, fibrillar form, and are formulated in a unique physiologic buffer that ensures maintenance of the collagen molecule’s structure and function,” as stated by Arthur Tallis, DPM, a Fellow of the American Professional Wound Care Association and the American College of Foot and Ankle Surgeons, who was a clinical investigator in the multi-center Phase 2b MATRIX study. Those interested in reading the full article should visit http://www.podiatrytoday.com/top-10-innovations-podiatry?page=3. The article will also be published in the August 2012 print issue of Podiatry Today.
As reported by Podiatry Today, “Dr. Tallis has applied Excellagen following surgical debridement in the presence of blood cells and platelets,” and that “Excellagen activates human platelets, triggering the release of platelet-derived growth factors (PDGF).” With regard to the practice of podiatry and patient compliance, it was noted that “Excellagen can save time for the physician and patient as dressing changes are required only once a week.” In terms of ease of application and use, it was stated that “additional advantages of Excellagen are that no thawing or mixing of components is required prior to use,” and that “one can easily apply the formulation to wounds of all sizes and shapes, and the product achieves complete, even wound coverage without dripping.”
For more information on Cardium Therapeutics, visit www.CardiumTHX.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html